Intact FGF23 and α-klotho during acute inflammation/sepsis in CKD patients

European Journal of Clinical Investigation

Volumn 46, Issue 3, 2016, Pages 234-241

  Dounousi, Evangelia ^a   Torino, Claudia ^b   Pizzini, Patrizia ^b   Cutrupi, Sebastiano ^b   Panuccio, Vincenzo ^b,c   D'Arrigo, Graziella ^b   Abd Elhafeez, Samar ^d   Tripepi, Giovanni ^b   Mallamaci, Francesca ^b,c   Zoccali, Carmine ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b CNR   (Italy)

^c Renal Unit   (Italy)

^d ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Acute inflammation; Carboxy FGF23; Chronic kidney disease; Intact FGF23; Klotho; Sepsis

Indexed keywords

25 HYDROXYVITAMIN D; 3 NITROTYROSINE; ALPHA KLOTHO PROTEIN; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; FERRITIN; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; IRON; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATE; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 25-HYDROXYVITAMIN D; 3-NITROTYROSINE; BETA GLUCURONIDASE; BIOLOGICAL MARKER; CALCITONIN; FIBROBLAST GROWTH FACTOR; IL6 PROTEIN, HUMAN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; TYROSINE; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; FEMALE; FERRITIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SEPSIS; SYNTHESIS; UPREGULATION; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; CHRONIC KIDNEY FAILURE; IMMUNOLOGY; METABOLISM; PROSPECTIVE STUDY;

ADULT; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CALCITONIN; CALCITRIOL; FEMALE; FERRITINS; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; INFLAMMATION; INTERLEUKIN-6; IRON; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE; VITAMIN D;

EID: 84957953317     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12588     Document Type: Article

References (37)

1. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013;75:503-33.
2. Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82:737-47.
3. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009;114:S34-42.
4. Zoccali C, Yilmaz MI, Mallamaci F. FGF23: a mature renal and cardiovascular risk factor? Blood Purif 2013;36:52-7.
5. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-3.
6. Dai B, David V, Martin A et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS ONE 2012;7:e44161.
7. Zanchi C, Locatelli M, Benigni A et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS ONE 2013;8:e70775.
8. Yilmaz MI, Sonmez A, Saglam M et al. Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy. Am J Nephrol 2014;40:208-14.
9. Fischer SS, Kempe DS, Leibrock CB et al. Hyperaldosteronism in Klotho-deficient mice. Am J Physiol Renal Physiol 2010;299:F1171-7.
10. Silswal N, Touchberry CD, Daniel DR et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 2014;307:E426-36.
11. Nagai R, Saito Y, Ohyama Y et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 2000;57:738-46.
12. Munoz MJ, Isakova T, Ricardo AC et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012;7:1155-62.
13. Tripepi G, Kollerits B, Leonardis D et al. Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD. J Am Soc Nephrol 2015;26:935-44.
14. Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutierrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS ONE 2015;10:e0122885.
15. Oh HJ, Nam BY, Lee MJ et al. Decreased circulating klotho levels in patients undergoing dialysis and relationship to oxidative stress and inflammation. Perit Dial Int 2015;35:43-51.
16. Yamazaki M, Kawai M, Miyagawa K et al. Interleukin-1-induced acute bone resorption facilitates the secretion of fibroblast growth factor 23 into the circulation. J Bone Miner Metab 2015;33:342-54.
17. Thurston RD, Larmonier CB, Majewski PM et al. Tumor necrosis factor and interferon-gamma down-regulate Klotho in mice with colitis. Gastroenterology 2010;138:1384-94.
18. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
19. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 2014;23:411-9.
20. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941-52.
21. Zoccali C, Curatola G, Panuccio V et al. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension 2014;64:1005-11.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
23. Ito N, Wijenayaka AR, Prideaux M et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol 2015;399:208-18.
24. Izquierdo MC, Perez-Gomez MV, Sanchez-Nino MD et al. Klotho, phosphate and inflammation/ageing in chronic kidney disease. Nephrol Dial Transplant 2012;27(Suppl. 4):iv6-10.
25. Moreno JA, Izquierdo MC, Sanchez-Nino MD et al. The inflammatory cytokines TWEAK and TNFalpha reduce renal klotho expression through NFkappaB. J Am Soc Nephrol 2011;22:1315-25.
26. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-6.
27. Zoccali C, Benedetto FA, Maas R et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002;13:490-6.
28. Zoccali C, Maas R, Cutrupi S et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 2007;22:801-6.
29. Iapichino G, Umbrello M, Albicini M et al. Time course of endogenous nitric oxide inhibitors in severe sepsis in humans. Minerva Anestesiol 2010;76:325-33.
30. Lopez A, Lorente JA, Steingrub J et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30.
31. Nakamura T, Saito Y, Ohyama Y et al. Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn J Pharmacol 2002;89:149-56.
32. Saito Y, Nakamura T, Ohyama Y et al. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 2000;276:767-72.
33. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002;3:753-66.
34. Chaaban H, Singh K, Huang J, Siryaporn E, Lim YP, Padbury JF. The role of inter-alpha inhibitor proteins in the diagnosis of neonatal sepsis. J Pediatr 2009;154:620-2.
35. Farrow EG, Yu X, Summers LJ et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011;108:E1146-55.
36. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013;28:1793-803.
37. Isakova T, Barchi-Chung A, Enfield G et al. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clin J Am Soc Nephrol 2013;8:1009-18.